A dual co-agonist that moved from diabetes and obesity programs toward a focus on fatty liver disease.
Also known as: MK-6024 · HM12525A · JNJ-64565111
Part of the Metabolic & GLP-1 peptides cluster
Overview
Efinopegdutide (MK-6024) is an investigational dual GLP-1/glucagon receptor co-agonist studied by Merck, more recently focused on non-alcoholic fatty liver disease. It is a long-acting peptide conjugate designed for once-weekly dosing. It is not authorized by Health Canada, and this page is educational only.
Source & context
Biological / chemical source: Synthetic peptide conjugate engineered for extended half-life
Primary research or clinical context: Investigational compound (Merck); studied in trials for non-alcoholic fatty liver disease and NASH — not authorized by Health Canada
From diabetes to liver disease
Efinopegdutide began as a candidate for type 2 diabetes and obesity before those indications were discontinued and development refocused on fatty liver disease. As a balanced dual agonist it engages both the GLP-1 and glucagon receptors, a mechanism reported to lower hepatic fat but also associated with gastrointestinal effects common to the class.
Regulatory context
Efinopegdutide has received Fast Track designation in the United States for NASH but remains investigational and is not authorized by Health Canada. This page describes its chemistry and program history for education only and makes no claim that it treats or cures liver disease, diabetes or obesity.
FAQ about Efinopegdutide
What is Efinopegdutide?+
Efinopegdutide (MK-6024) is an investigational dual GLP-1/glucagon receptor co-agonist studied by Merck, more recently focused on non-alcoholic fatty liver disease. It is a long-acting peptide conjugate designed for once-weekly dosing. It is not authorized by Health Canada, and this page is educational only.
Is Efinopegdutide an approved medicine?+
Efinopegdutide is discussed here as a research / educational topic. Investigational compound (Merck); studied in trials for non-alcoholic fatty liver disease and NASH — not authorized by Health Canada. This is not medical advice.
What is the typical length of Efinopegdutide?+
Efinopegdutide is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.